Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 11

1.

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.

Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH.

Am J Clin Nutr. 2012 Feb;95(2):297-308. doi: 10.3945/ajcn.111.024927. Epub 2011 Dec 7.

2.

Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP).

Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, Tam PY, Troupin B, Day WW.

Obesity (Silver Spring). 2012 Feb;20(2):330-42. doi: 10.1038/oby.2011.330. Epub 2011 Nov 3.

3.

Long-term persistence of hormonal adaptations to weight loss.

Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, Proietto J.

N Engl J Med. 2011 Oct 27;365(17):1597-604. doi: 10.1056/NEJMoa1105816.

4.

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.

Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW.

Lancet. 2011 Apr 16;377(9774):1341-52. doi: 10.1016/S0140-6736(11)60205-5. Epub 2011 Apr 8. Erratum in: Lancet. 2011 Apr 30;377(9776):1494.

PMID:
21481449
5.

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E; COR-I Study Group.

Lancet. 2010 Aug 21;376(9741):595-605. doi: 10.1016/S0140-6736(10)60888-4. Epub 2010 Jul 29. Erratum in: Lancet. 2010 Oct 23;376(9750):1392. Lancet. 2010 Aug 21;376(9741):594.

PMID:
20673995
6.

Multicenter, placebo-controlled trial of lorcaserin for weight management.

Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, Bays H, Shanahan WR; Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group.

N Engl J Med. 2010 Jul 15;363(3):245-56. doi: 10.1056/NEJMoa0909809.

7.

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.

Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM.

Lancet. 2009 Nov 14;374(9702):1677-86. doi: 10.1016/S0140-6736(09)61457-4. Epub 2009 Oct 29. Erratum in: Lancet. 2009 Dec 19;374(9707):2054.

8.

The financial burden of overweight and obesity among elderly Americans: the dynamics of weight, longevity, and health care cost.

Yang Z, Hall AG.

Health Serv Res. 2008 Jun;43(3):849-68. doi: 10.1111/j.1475-6773.2007.00801.x.

9.

The health and cost consequences of obesity among the future elderly.

Lakdawalla DN, Goldman DP, Shang B.

Health Aff (Millwood). 2005;24 Suppl 2:W5R30-41.

10.

The impact of obesity on rising medical spending.

Thorpe KE, Florence CS, Howard DH, Joski P.

Health Aff (Millwood). 2004 Jul-Dec;Suppl Web Exclusives:W4-480-6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk